• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Amyotrophic Lateral Sclerosis Pipeline Highlights - 2014 Update Product Image

Amyotrophic Lateral Sclerosis Pipeline Highlights - 2014 Update

  • Published: May 2014
  • Fore Pharma

The latest report Amyotrophic Lateral Sclerosis Pipeline Highlights – 2014 Update, provides most up-to-date information on key pipeline molecules in the global Amyotrophic Lateral Sclerosis market. It covers emerging therapies for Amyotrophic Lateral Sclerosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Amyotrophic Lateral Sclerosis pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Amyotrophic Lateral Sclerosis pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Amyotrophic Lateral READ MORE >

1. Amyotrophic Lateral Sclerosis Pipeline by Stages
2. Amyotrophic Lateral Sclerosis Pipeline by Drug Class
3. Amyotrophic Lateral Sclerosis Pipeline by Company
4. Amyotrophic Lateral Sclerosis Phase 3 Clinical Trial Insights
5. Amyotrophic Lateral Sclerosis Phase 2 Clinical Trial Insights
6. Amyotrophic Lateral Sclerosis Phase 1 Clinical Trial Insights
7. Amyotrophic Lateral Sclerosis Preclinical Research Insights
8. Amyotrophic Lateral Sclerosis Discovery Stage Insights
9. Appendix
10. Research Methodology
Table 1: Amyotrophic Lateral Sclerosis Phase 3 Clinical Trials, 2014
Table 2: Amyotrophic Lateral Sclerosis Phase 2 Clinical Trials, 2014
Table 3: Amyotrophic Lateral Sclerosis Phase 1 Clinical Trials, 2014
Table 4: Amyotrophic Lateral Sclerosis Preclinical Research, 2014
Table 5: Amyotrophic Lateral Sclerosis Discovery Stage, 2014
Figure 1: Amyotrophic Lateral Sclerosis Pipeline Molecules by Clinical Trials Stage, 2014
Figure 2: Amyotrophic Lateral Sclerosis Pipeline Molecules by Drug Class, 2014
Figure 3: Amyotrophic Lateral Sclerosis Pipeline Molecules by Company, 2014
Figure 4: Amyotrophic Lateral Sclerosis Phase 3 Clinical Trial Highlights, 2014
Figure 5: Amyotrophic Lateral Sclerosis Phase 2 Clinical Trial Highlights, 2014
Figure 6: Amyotrophic Lateral Sclerosis Phase 1 Clinical Trial Highlights, 2014
Figure 7: Amyotrophic Lateral Sclerosis Preclinical Research Highlights, 2014
Figure 8: Amyotrophic Lateral Sclerosis Discovery Stage Highlights, 2014

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos